prasugrel + clopidogrel
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Coronary Artery Disease
Conditions
Coronary Artery Disease
Trial Timeline
Mar 1, 2010 → Aug 1, 2011
NCT ID
NCT01107925About prasugrel + clopidogrel
prasugrel + clopidogrel is a phase 1 stage product being developed by Daiichi Sankyo for Coronary Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01107925. Target conditions include Coronary Artery Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01327534 | Phase 3 | Completed |
| NCT01260584 | Approved | Completed |
| NCT01107912 | Phase 1 | Completed |
| NCT01107925 | Phase 1 | Completed |
| NCT01014624 | Approved | Completed |
| NCT00910299 | Phase 2 | Terminated |
| NCT00830960 | Phase 3 | Completed |
| NCT00642174 | Phase 2 | Completed |
| NCT00385944 | Phase 2 | Completed |
| NCT00097591 | Phase 3 | Completed |
Competing Products
20 competing products in Coronary Artery Disease